Cargando…

Current Status and Advancements in Platelet-Rich Plasma Therapy

Platelet-rich plasma (PRP) as a treatment modality has been around for the last four decades, but only truly gained popularity over the last 10 to 15 years in medicine, in a variety of fields ranging from regenerative medicine to infertility treatment. It has gained popularity, especially in treatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pretorius, Jacques, Habash, Mohammed, Ghobrial, Bishoy, Alnajjar, Rafee, Ellanti, Prasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652151/
https://www.ncbi.nlm.nih.gov/pubmed/38021947
http://dx.doi.org/10.7759/cureus.47176
_version_ 1785136148626014208
author Pretorius, Jacques
Habash, Mohammed
Ghobrial, Bishoy
Alnajjar, Rafee
Ellanti, Prasad
author_facet Pretorius, Jacques
Habash, Mohammed
Ghobrial, Bishoy
Alnajjar, Rafee
Ellanti, Prasad
author_sort Pretorius, Jacques
collection PubMed
description Platelet-rich plasma (PRP) as a treatment modality has been around for the last four decades, but only truly gained popularity over the last 10 to 15 years in medicine, in a variety of fields ranging from regenerative medicine to infertility treatment. It has gained popularity, especially in treating musculoskeletal conditions where the bulk of research has been performed and published. There is level I evidence available supporting its efficacy in the treatment of osteoarthritis (OA), epicondylitis, bursitis, compressive neuropathy, plantar fasciitis, muscular injuries and osteochondral lesions. Most published research with regards to PRP has been focused on knee OA (limited research in shoulder, elbow, and foot and ankle OA), lateral epicondylitis and carpal tunnel syndrome, whereas spinal and hand conditions have limited research available. Tendinopathies and partial tendon tears have conflicting evidence available, with level I evidence supporting PRP’s use in rotator cuff tendinopathies and tears, with contradictory level I evidence discouraging its use in patella and Achilles tendinopathies and tears. The available evidence regarding the use of PRP continues to produce conflicting results, but despite this, there is an ongoing increase in the popularity and use of PRP in patients with musculoskeletal conditions.
format Online
Article
Text
id pubmed-10652151
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106521512023-10-17 Current Status and Advancements in Platelet-Rich Plasma Therapy Pretorius, Jacques Habash, Mohammed Ghobrial, Bishoy Alnajjar, Rafee Ellanti, Prasad Cureus Physical Medicine & Rehabilitation Platelet-rich plasma (PRP) as a treatment modality has been around for the last four decades, but only truly gained popularity over the last 10 to 15 years in medicine, in a variety of fields ranging from regenerative medicine to infertility treatment. It has gained popularity, especially in treating musculoskeletal conditions where the bulk of research has been performed and published. There is level I evidence available supporting its efficacy in the treatment of osteoarthritis (OA), epicondylitis, bursitis, compressive neuropathy, plantar fasciitis, muscular injuries and osteochondral lesions. Most published research with regards to PRP has been focused on knee OA (limited research in shoulder, elbow, and foot and ankle OA), lateral epicondylitis and carpal tunnel syndrome, whereas spinal and hand conditions have limited research available. Tendinopathies and partial tendon tears have conflicting evidence available, with level I evidence supporting PRP’s use in rotator cuff tendinopathies and tears, with contradictory level I evidence discouraging its use in patella and Achilles tendinopathies and tears. The available evidence regarding the use of PRP continues to produce conflicting results, but despite this, there is an ongoing increase in the popularity and use of PRP in patients with musculoskeletal conditions. Cureus 2023-10-17 /pmc/articles/PMC10652151/ /pubmed/38021947 http://dx.doi.org/10.7759/cureus.47176 Text en Copyright © 2023, Pretorius et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Physical Medicine & Rehabilitation
Pretorius, Jacques
Habash, Mohammed
Ghobrial, Bishoy
Alnajjar, Rafee
Ellanti, Prasad
Current Status and Advancements in Platelet-Rich Plasma Therapy
title Current Status and Advancements in Platelet-Rich Plasma Therapy
title_full Current Status and Advancements in Platelet-Rich Plasma Therapy
title_fullStr Current Status and Advancements in Platelet-Rich Plasma Therapy
title_full_unstemmed Current Status and Advancements in Platelet-Rich Plasma Therapy
title_short Current Status and Advancements in Platelet-Rich Plasma Therapy
title_sort current status and advancements in platelet-rich plasma therapy
topic Physical Medicine & Rehabilitation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652151/
https://www.ncbi.nlm.nih.gov/pubmed/38021947
http://dx.doi.org/10.7759/cureus.47176
work_keys_str_mv AT pretoriusjacques currentstatusandadvancementsinplateletrichplasmatherapy
AT habashmohammed currentstatusandadvancementsinplateletrichplasmatherapy
AT ghobrialbishoy currentstatusandadvancementsinplateletrichplasmatherapy
AT alnajjarrafee currentstatusandadvancementsinplateletrichplasmatherapy
AT ellantiprasad currentstatusandadvancementsinplateletrichplasmatherapy